Generics

Press enter to search
Close search
Open Menu

Generics

News and information on generic drugs sold in retail pharmacies, as well as their suppliers.

Micro Labs, Saptalis ink generics deal, launch first product

Micro Labs USA and Saptalis Pharmaceuticals have formed a strategic collaboration to launch single-source and multisource generics in the United States.

A gold trophy for an award.

Mockingbird Pharma receives NCDQS accreditation

Mockingbird Pharma is the second facility to meet NCDQS' strict accreditation approval criteria.

A pharmacist handing a prescription to a patient.

Although polices have been introduced to increase the use of generics and biosimilars, large differences remain in the price and uptake of these medicines between countries.

A man holding an FDA approved sign.

Tizanidine hydrochloride ​​​​​​​had a market value of roughly $28 million for the 12 months ended September 2019, according to IQVIA.

Vilazodone hydrochloride tablets and empagliflozin tablets had a market value of $469 million and roughly $3.4 billion respectively, for the 12 months ended September 2019.

An illustration of an envelope with a paper that has a check mark.

The generic is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

A pharmacy stock room.

Potassium citrate ER tablets have a market value of roughly $75 million, according to IQVIA.

A pharmacy stock room.

Ironwood and Allergan will grant Sandoz a license to market its 145 mcg and 290 mcg generic of Linzess beginning Feb. 5, 2030.

A pharmacy stock room.

In partnership with Merck, Prasco is launching an authorized generic of NuvaRing.

A medicine cabinet with pill bottles.

Haloperidol tablets had a market value of approximately $41 million for the 12 months ended August 2019, according to IQVIA.

FDA headquarters.

Ten biosimilars were approved in 2019, bringing the number of approved biosimilars to 26 since 2015.

The words approved in caps and red letters.

Twenty-nine of the 48 novel drug approvals of 2019, or 60%, were designated in one or more expedited categories of Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval.

A pharmacy stock room.

Fluvoxamine tablets had a market value of approximately $28 million for the 12 months ended September 2019.

A case of injectables.

The Nitropress brand and generics had a market value of approximately $8 million for the most recent 12 months ended October 2019.

Show More